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Tear Fluid Pharmacokinetics Following Oral Prednisone Administration
in Dogs With and Without Conjunctivitis
Abstract
Purpose: To describe the pharmacokinetics (PK) of prednisone and prednisolone in tear fluid of dogs
receiving oral prednisone at anti-inflammatory to immunosuppressive doses and to assess the impact of
induced conjunctivitis on lacrimal drug levels.
Methods: Six healthy Beagle dogs were administered 4 courses of prednisone at 0.5, 1.0, 2.0, and 4.0 mg/kg
given orally once a day for 5 days. At steady state, topical histamine was applied to induce mild (1 mg/mL) or
severe (375 mg/mL) conjunctivitis in 1 eye of each dog and tear samples were collected from both eyes at
selected times. Prednisone and prednisolone were quantified in tears by liquid chromatography-mass
spectrometry.
Results: Lacrimal prednisone and prednisolone concentrations ranged from 2 to 523 ng/mL and 5 to 191 ng/
mL, respectively. Drug concentrations were overall greater in dogs receiving higher doses of prednisone, but
were not correlated with tear flow rate. Eyes with conjunctivitis often had larger amounts of prednisone and
prednisolone in tear fluid compared to control eyes (up to +64%), but differences were not statistically
significant. Significantly greater, but clinically insignificant, levels of prednisolone were found in eyes with
severe versus mild conjunctivitis for oral prednisone doses ≥1.0 mg/kg.
Conclusions: Disruption of the blood–tear barrier with conjunctivitis did not significantly affect drug levels in
tears. Based on drug PK in tears, oral prednisone is likely safe for the management of reflex uveitis and ocular
surface diseases. However, further prospective trials using systemic corticotherapy in diseased animals are
warranted to confirm findings from this preclinical study.
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Tear Fluid Pharmacokinetics Following Oral Prednisone
Administration in Dogs With and Without Conjunctivitis
Lionel Sebbag,1,2 Yuqi Yan,3 Joe S. Smith,2,4 Rachel A. Allbaugh,1 Larry W. Wulf,5 and Jonathan P. Mochel2
Abstract
Purpose: To describe the pharmacokinetics (PK) of prednisone and prednisolone in tear fluid of dogs receiving
oral prednisone at anti-inflammatory to immunosuppressive doses and to assess the impact of induced con-
junctivitis on lacrimal drug levels.
Methods: Six healthy Beagle dogs were administered 4 courses of prednisone at 0.5, 1.0, 2.0, and 4.0 mg/kg given
orally once a day for 5 days. At steady state, topical histamine was applied to induce mild (1 mg/mL) or severe
(375 mg/mL) conjunctivitis in 1 eye of each dog and tear samples were collected from both eyes at selected times.
Prednisone and prednisolone were quantified in tears by liquid chromatography-mass spectrometry.
Results: Lacrimal prednisone and prednisolone concentrations ranged from 2 to 523 ng/mL and 5 to 191 ng/mL,
respectively. Drug concentrations were overall greater in dogs receiving higher doses of prednisone, but were
not correlated with tear flow rate. Eyes with conjunctivitis often had larger amounts of prednisone and pred-
nisolone in tear fluid compared to control eyes (up to +64%), but differences were not statistically significant.
Significantly greater, but clinically insignificant, levels of prednisolone were found in eyes with severe versus
mild conjunctivitis for oral prednisone doses ‡1.0 mg/kg.
Conclusions: Disruption of the blood–tear barrier with conjunctivitis did not significantly affect drug levels in
tears. Based on drug PK in tears, oral prednisone is likely safe for the management of reflex uveitis and ocular
surface diseases. However, further prospective trials using systemic corticotherapy in diseased animals are
warranted to confirm findings from this preclinical study.
Keywords: pharmacokinetics, prednisone, prednisolone, tear film, canine, blood–tear barrier
Introduction
Prednisone is a corticosteroid with a wide range ofpharmacological indications that is commonly used for
the treatment of inflammatory and immune-mediated dis-
eases in human and veterinary medicine. In ophthalmology,
corticosteroids can alleviate ocular inflammation and help
prevent devastating sequelae that could be painful or vision
threatening.1 Of the various routes of administration, sys-
temic therapy is generally recommended when the target
tissue cannot be reached with topical ophthalmic cortico-
steroids (eg, eyelids, posterior segment, orbit), or as a com-
plement to topical medications in cases of anterior uveitis.2
Systemically administered medications not only can readily
distribute to the vascular tissues of the eye but can also affect
the ocular surface if the drug reaches the tear compartment.
For instance, oral doxycycline can be used as adjunctive
therapy for keratomalacia in dogs and horses,3,4 while oral
famciclovir is highly effective in managing herpetic kerato-
conjunctivitis in cats.5,6
For oral prednisone, detection of steroid levels in the tear
film could support the use of systemic corticotherapy for
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adjunctive treatment of inflammatory diseases such as
chronic superficial keratitis, immune-mediated keratitis, and
keratoconjunctivitis sicca. Conversely, lacrimal levels of
corticosteroids could inhibit corneal wound healing and
potentiate infection.7,8 This therapeutic dilemma is exem-
plified in patients with ulcerative keratitis and concurrent
reflex uveitis: systemic steroids are superior to nonsteroidal
anti-inflammatory medications for controlling severe uveitis
and preventing devastating sequelae,9 yet, ulceration could
worsen and result in corneal perforation if wound healing is
compromised and infection is potentiated.
The main goal of the study was to describe the pharma-
cokinetics (PK) of prednisone and its active metabolite pred-
nisolone in tear fluid of dogs following oral administration at
doses ranging from anti-inflammatory to immunosuppressive
use (0.5–4 mg/kg/day). We hypothesized that prednisone and
prednisolone would be quantifiable in canine tear fluid and
concentrations would be greater with increasing oral dosing.
In an effort to make the findings of this study more clinically
relevant, a secondary objective was to determine the impact
of conjunctivitis on drug concentrations in tears.
Indeed, conjunctivitis, a common bystander of most oc-
ular diseases, increases conjunctival vascular permeability
and therefore enhances vascular leakage of plasma com-
pounds onto the ocular surface.10,11 We hypothesized that
tear concentrations would be greater in eyes with conjunc-
tivitis (ie, compromised blood–tear barrier) compared with
healthy eyes.
Methods
Animals
Six Beagle dogs were included in the study. All were
spayed females of 1.5–2 years old and weighing 7.5–10 kg.
Before study inclusion, dogs were confirmed to be healthy
based on physical and ophthalmic examination, complete
blood count, serum chemistry, and urinalysis. The study was
approved by the Institutional Animal Care and Use Com-
mittee of Iowa State University, and adhered to the Asso-
ciation for Research in Vision and Ophthalmology statement
for the Use of Animals in Ophthalmic and Vision Research.
Procedures
Over a period of 2 months, all dogs received 4 successive
dosing regimens of oral prednisone (CadistaTM predniSONE
tablets; Jubilant Cadista Pharmaceuticals, Inc., Salisbury,
MD), characterized by 5 days of drug administration inter-
rupted by 9 days washout period, which included (1) 0.5 mg/kg
once daily for 5 days; (2) 1.0 mg/kg once daily for 5 days;
(3) 2.0 mg/kg once daily for 5 days; and (4) 4.0 mg/kg once
daily for 5 days. The following procedures were performed
on day 4 of each dosing regimen, a time chosen to ensure that
steady state drug levels were reached12:
 Induction of conjunctivitis in 1 eye: Histamine oph-
thalmic solutions were formulated by mixing histamine
powder (histamine dihydrochloride, FCC grade, Acros
Organics, Geel, Belgium) with 1.4% polyvinyl alcohol
lubricating eye drops (Artificial tears solution; Rugby,
Rockville Center, NY) in a sterile manner under a
laminar flow hood. Twenty minutes before prednisone
administration, a single drop of histamine solution was
applied to one randomly selected eye in each dog, while
the other eye received artificial tears (Control). This
ocular selection was kept constant throughout the study.
Histamine rapidly induced conjunctivitis (<1 min) that
was either mild (n= 3 dogs, 1.0 mg/mL histamine so-
lution; Fig. 1A) or severe (n= 3 dogs, 375 mg/mL his-
tamine solution; Fig. 1B), as previously described.11
Conjunctivitis was maintained throughout the 12 h col-
lection period by repeating topical histamine adminis-
tration every 1–4 h as needed to maintain effect. Topical
0.035% ketotifen fumarate (Zaditor; Novartis Phar-
maceuticals Corporation, East Hanover, NJ) was in-
stilled onto each eye at the end of the day to control any
residual conjunctival swelling.
 Tear collection: Tear fluid was sampled simultaneously
in both eyes before prednisone administration (t= 0 min)
and at 15, 30, 60, 90, 120, 240, 480, and 720 min fol-
lowing drug administration. The bent tip of a Schirmer
tear strip (Eye Care Product Manufacturing, LLC, Tuc-
son, AZ) was placed in the ventrolateral conjunctival
fornix of each eye. While recording the test duration with
a stopwatch, each Schirmer strip was removed and
transferred into a 2-mL Eppendorf tube when the 20-mm
mark of wetness was reached, as to standardize the vol-
ume of tears collected in each sample. The distal portion
of each strip (25–35 mm marks, not wetted with tears)
was spiked with 5mL internal standard (prednisone-d7;
Toronto Research Chemicals, North York, Canada) pre-
pared as 10 ng/mL solution in 1:1 acetonitrile:water, and
samples were stored at -80C until analysis.
 Preparation of tear samples for analysis: The details of
tear fluid extraction are described in the Appendix Table
A1. In brief, both centrifugation and elution in solvent
were used as complementary methods to extract the
drug from Schirmer strips.13 Wetted strips containing
tear fluid and internal standard were first centrifuged to
retrieve the majority of absorbed tear fluid, followed by
cutting and shredding the strips into small pieces and
eluting them in methyl tert-butyl ether (MTBE). Of
note, this particular solvent was chosen based on its
superior ability to extract prednisone from Schirmer
strips compared with methanol, acetonitrile, and water
(small pilot study, data not shown).
 Liquid chromatography–mass spectrometry: Before
study initiation, blank tears were collected from the same
Beagle dogs using polyvinyl ophthalmic sponges as
previously described.14 Eight standard curve solutions
FIG. 1. Topical histamine rapidly induced conjunctivitis
(<1 min) that was either mild [(A); 1.0 mg/mL solution] or
severe [(B); 375 mg/mL solution]. Color images are avail-
able online.
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were prepared by spiking blank canine tears with stock
solutions of prednisone/prednisolone (Cerrilliant, Round
Rock, TX) to obtain the following concentrations: 1, 2, 5,
10, 20, 50, 100, and 200 ng/mL. Calibration curve sam-
ples were processed in a similar manner to biological
tear samples, which involved wetting Schirmer strips
with standard solutions until the 20-mm mark was
reached, spiking prednisone-d7 internal standard onto the
distal (dry) portion of the strips, centrifugation and elu-
tion in MTBE, and so on (see Appendix Table A1 for
details). Concentrations of prednisolone and prednisone
in canine tears were determined using high-pressure
liquid chromatography (Agilent 1100 Pump, Column
Compartment, and Autosampler, Santa Clara, CA) with
ion trap mass spectrometry detection (LTQ; Thermo
Scientific, San Jose, CA). The injection volume was set
to 20mL. The mobile phases consisted of A: 0.1% formic
acid in water and B: 0.1% formic acid in acetonitrile at a
flow rate of 0.25 mL/min. The mobile phase began at
20% B with a linear gradient to 95% B in 5.0 min, which
was maintained for 2 min at 0.325 mL/min, followed by
reequilibration to 20% B at 0.325 mL/min for 3.5 min.
Separation was achieved with an ACE UltraCore C18
column, 100 mm· 2.1 mm, 2.5mm particles (Mac-Mod
Analytical, Chadds Cord, PA) maintained at 40C. The
chromatographic peaks for the internal standard, pred-
nisone, and prednisolone (each eluted at 4.69– 0.05 min)
were integrated using Xcalibur software (Thermo Sci-
entific). Drug quantitation was based on linear regression
analysis of calibration curves (weighted 1/X) using the
analyte to internal standard area ratio. Calibration curves
exhibited a correlation coefficient (r2) exceeding 0.995
across the concentration range. The limits of quantitation
for prednisone and prednisolone were 2 ng/mL and
5 ng/mL, respectively, while the limits of detection for
prednisone and prednisolone were 0.5 and 1 ng/mL,
respectively.
Data analysis
Noncompartmental analysis of prednisone and predniso-
lone PK was conducted with Phoenix software (WinNonlin,
version 8.0; Pharsight Corporation, CA) to determine the
maximum concentration (Cmax), time to maximum concen-
tration (Tmax), and area under the curve from time zero to
time of last measurable concentration (AUClast).
The Shapiro–Wilk test was used to assess data for normality.
Non-normally distributed data were expressed as median and
95% central range (2.5–97.5th percentiles) and were analyzed
with nonparametric statistics. Normally, distributed data are
expressed as mean– standard deviation (95% central range)
and were analyzed with parametric statistics.
Associations between tear flow rate and lacrimal con-
centrations of prednisone or prednisolone were assessed
with the Spearman’s correlation test. The Student t-test was
used to assess differences in AUClast between eyes with
mild or severe conjunctivitis. For each oral dose and for
each PK parameter (AUClast, Cmax, Tmax), differences be-
tween control and conjunctivitis eyes (mild + severe) were
assessed with the Student t test or Mann–Whitney test. For
each PK parameter, differences among oral doses (0.5, 1.0,
2.0, and 4.0 mg/kg) were assessed with the one-way analysis
of variance or Kruskal–Wallis test. Statistical analysis was
performed using SigmaPlot 14.0 (Systat Software, Inc., San
Jose, CA), and values P< 0.05 were considered statistically
significant.
Results
Following oral administration of prednisone, both pred-
nisone and prednisolone were quantifiable in tear fluid,
with concentrations ranging from 2 to 523 ng/mL and 5
to 191 ng/mL, respectively. Lacrimal concentrations were
not correlated with tear flow rate for either prednisone
(P‡ 0.412) or prednisolone (P ‡ 0.388). However, higher
doses of oral prednisone resulted in higher tear concentra-
tions of both steroids, as depicted by the individual con-
centration–time curves in Fig. 2. In fact, the overall drug
exposure in tears (depicted by AUClast) was statistically
different among the 4 doses for both prednisone (P £ 0.002;
Fig. 3A) and prednisolone (P £ 0.001; Fig. 3B). Similarly,
statistical differences were detected among oral doses for
prednisone Cmax (P= 0.008) and for prednisolone Cmax
(P= 0.003) and Tmax (P = 0.039; Table 1).
In general, eyes with conjunctivitis showed a trend for
larger concentrations of prednisone and prednisolone in tear
fluid compared with control eyes (Figs. 2 and 3), with dif-
ferences in average concentrations ranging from +5% to
+64%. However, differences in AUClast between control and
conjunctivitis eyes were not statistically significant for ei-
ther prednisone (P ‡ 0.095; Fig. 3A) or prednisolone
(P‡ 0.485; Fig. 3B). The severity of conjunctivitis did have
an impact on lacrimal concentrations, as significantly
greater levels of prednisolone were found in eyes with se-
vere versus mild conjunctivitis for oral doses 1–4 mg/kg/day
(P£ 0.042; Fig. 4), although these changes were not con-
sidered to be large enough to be clinically relevant.
Discussion
The present study describes, for the first time, the tear film
PK of prednisone and prednisolone in veterinary medicine.
Tear film concentrations of prednisone and prednisolone
varied from 2 to 523 ng/mL and 5 to 191 ng/mL, respec-
tively, with higher doses of oral prednisone leading to higher
lacrimal levels of both steroids. The question remains whe-
ther concentrations of the active metabolite (prednisolone)
are relevant in clinical patients, that is potentially beneficial
or detrimental to managing ocular surface diseases.
Overall, tear film prednisolone levels were ‡10-9 M (ie,
0.4 ng/mL) in all dogs throughout the 12-h sampling time, a
concentration shown to decrease the expression of delete-
rious cytokines (tumor necrosis factor-a, interleukin-6) and
matrix metalloproteinases in a rat model of keratitis.15
Therefore, oral prednisone might have therapeutic benefits
in managing corneal inflammation, assuming similar
exposure-response between species.
In fact, although the use of corticosteroid in infectious
keratitis remains controversial,16 some authors believe that a
judicious use of corticosteroids (combined with the ap-
propriate antimicrobial) could improve the outcome of
keratitis as it reduces damage caused by the host’s inflam-
matory response, decreases corneal scarring, and inhibits
neovascularization.17,18 From a safety viewpoint, the use
of corticosteroids is known to potentially delay corneal
wound healing and exacerbate signs of ocular infection.
CORTICOSTEROID PHARMACOKINETICS IN TEARS 3
F
IG
.
2
.
T
ea
r
fi
lm
co
n
ce
n
tr
at
io
n
s
(m
ea
n
+
st
an
d
ar
d
d
ev
ia
ti
o
n
)
o
f
p
re
d
n
is
o
n
e
(A
,
B
)
an
d
p
re
d
n
is
o
lo
n
e
(C
,
D
)
in
d
o
g
s
re
ce
iv
in
g
o
ra
l
p
re
d
n
is
o
n
e
at
0
.5
m
g
/k
g
o
n
ce
d
ai
ly
(b
la
ck
li
n
e,
ci
rc
le
s)
,
1
.0
m
g
/k
g
o
n
ce
d
ai
ly
(r
ed
li
n
es
,
d
o
w
n
tr
ia
n
g
le
s)
,
2
.0
m
g
/k
g
o
n
ce
d
ai
ly
(g
re
en
li
n
es
,
sq
u
a
re
s)
,
an
d
4
.0
m
g
/k
g
o
n
ce
d
ai
ly
(b
lu
e
li
n
es
,
u
p
tr
ia
n
g
le
s)
.
T
h
e
co
n
ce
n
tr
at
io
n
s
ar
e
d
ep
ic
te
d
fo
r
co
n
tr
o
l
ey
es
(A
,
C
)
an
d
ey
es
w
it
h
ex
p
er
im
en
ta
ll
y
in
d
u
ce
d
co
n
ju
n
ct
iv
it
is
(B
,
D
).
O
f
n
o
te
,
th
e
co
n
ju
n
ct
iv
it
is
g
ro
u
p
in
cl
u
d
es
ey
es
w
it
h
m
il
d
an
d
se
v
er
e
co
n
ju
n
ct
iv
it
is
.
C
o
lo
r
im
ag
es
ar
e
av
ai
la
b
le
o
n
li
n
e.
4
FIG. 3. Box-and-whiskers
plots depicting the area under
the tear concentration–time
curve from time zero to time
of last measurable concen-
tration (AUClast). Each plot
depicts the mean (dotted
line), median (solid line),
2.5th percentile (lower whis-
ker), 25th percentile (lower
limit of box), 75th percentile
(upper limit of box), and
97.5th percentile (upper
whisker). Data for predni-
sone (A) and prednisolone
(B) are shown for all 4 oral
doses of prednisone (0.5–
4.0 mg/kg) in both control
eyes (white boxes) and eyes
with experimentally induced
conjunctivitis (dark gray). Of
note, the conjunctivitis group
includes eyes with mild and
severe conjunctivitis. Within
the same drug dose, com-
parisons between control and
conjunctivitis eyes (t test)
are described with P values
above the plots. Within the
same ocular group (control or
conjunctivitis), differences
among doses (one-way anal-
ysis of variance) are depicted
with symbols to demonstrate
statistically greater AUClast
compared to dose 1 (#), dose
2 ({), and dose 3 ({).
Table 1. Mean – Standard Deviation of the Maximal Concentration (Cmax) and Time to Reach Cmax (Tmax)
for Prednisone and Prednisolone in Control and Conjunctivitis Eyes
Prednisone Prednisolone
Cmax (ng/mL) Tmax (min) Cmax (ng/mL) Tmax (min)
Dose 1 (0.5 mg/kg)
Control 23.2 – 13.4 77.5 – 89.7 19.2 – 19.5 115.0 – 99.3
Conjunctivitis 55.1 – 68.1 87.5 – 85.1 22.4 – 26.7 130.0 – 86.3
Dose 2 (1.0 mg/kg)
Control 47.7 – 26.4 140.0– 187.3 29.2 – 24.9 215.0 – 257.0
Conjunctivitis 48.1 – 25.5 87.5 – 85.1 37.1 – 32.1 145.0 – 166.9
Dose 3 (2.0 mg/kg)
Control 91.7 – 74.7 127.5– 97.6 75.3 – 64.3 420.0 – 211.3#
Conjunctivitis 137.2– 115.5 65.0 – 22.6 62.7 – 31.3 320.0 – 196.0
Dose 4 (4.0 mg/kg)
Control 116– 67.2# 127.5– 93.8 123.6 – 47.8#,{ 160.0 – 92.3
Conjunctivitis 204.3– 173.5 120.0– 180.7 120.0 – 38.1#,{,{ 160.0 – 92.3
Within the same drug dose, comparisons between control and conjunctivitis eyes did not reveal any statistical differences (P> 0.05).
Within the same ocular group (control or conjunctivitis), differences among doses are depicted with symbols to demonstrate statistically
greater values compared to dose 1 (#), dose 2 ({), and dose 3 ({).
5
In vitro, inhibition of corneal wound healing in dogs is only
reported for prednisolone concentrations that are much
higher (‡620 mg/mL)19 than the ones reported herein.
In vivo, topical corticosteroid use can be detrimental in
patients with ulcerative keratitis2 although tear film con-
centrations following topical 1% prednisolone acetate are
unknown to date in any species. Data extrapolation from
PK of 0.3% ciprofloxacin in dogs20 show that (1) topical 1%
prednisolone acetate could reach concentrations as high as
909mg/mL, which is 1,000- to 10,000-fold greater than drug
levels noted in the present study; and (2) topical 1% pred-
nisolone acetate (applied every 6 h) could result in drug ex-
posure over 12 h that is 14,000–27,000-fold and 3,300–5,300-
fold greater than oral prednisone given at anti-inflammatory
dose (0.5–1 mg/kg/day) or immunosuppressive dose (2–
4 mg/kg/day), respectively.
Of note, drug exposure over time is more relevant than
single lacrimal concentrations (eg, Cmax) given differences
in pharmacological disposition between topical and oral
routes. While the ocular bioavailability of topical adminis-
tration is <10%–20% given efficient washout by tears,21 oral
administration could be considered as a form of sustained-
release at the ocular surface through lacrimal gland diffusion
and conjunctival leakage.
As for the negative impact on the immune system, there is
no consensus on what concentration is considered harmful.
In one study, prednisolone levels as low as 0.005 mg/mL
were shown to reduce the phagocytosis function of human
FIG. 4. Bar charts depict-
ing mean + standard devia-
tion of area under the tear
concentration-time curve
from time zero to time of last
measurable concentration
(AUClast). Data for tear con-
centrations of prednisone
(A) and prednisolone (B) are
shown for all 4 oral doses of
prednisone (0.5–4.0 mg/kg)
in eyes with experimentally
induced mild conjunctivitis
(light gray) or severe con-
junctivitis (dark gray).
Within the same dose, sta-
tistical comparisons between
mild and severe conjunctivi-
tis (t test) are described with
P values above the plots, and
statistical significance
(P< 0.05) is depicted with an
asterisk (*).
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leucocytes,22 while prednisolone concentrations as high as
4.32 mg/mL did not impact leucocyte phagocytosis or bac-
tericidal activity in another study.23
Conjunctivitis is a common disorder in dogs that develops
concurrently to most ocular diseases, whether affecting the
adnexa (eg, blepharitis), ocular surface (eg, corneal ulcer),
or intraocular tissues (eg, uveitis). With conjunctivitis,
plasma constituents tend to ‘‘leak’’ into the tear compart-
ment as the permeability of conjunctival vessels is typically
increased.10,11 This breakdown of the blood–tear barrier
explains the large quantities of albumin in tears of diseased
eyes, regardless of the underlying etiology of conjunctivitis
(eg, dry eye, corneal ulcer, allergies).24,25 Thus, to make the
present PK findings more clinically relevant, conjunctivitis
was experimentally induced in selected canine eyes using a
recently described model.11
Lacrimal levels of prednisone and prednisolone were
overall higher in conjunctivitis versus control eyes, with
greater disease severity leading to generally greater drug
levels in tears, especially for prednisolone. However, dif-
ferences between control versus conjunctivitis eyes were
not statistically significant, and were fairly minimal (up to
64% increase) when compared to plasma albumin (up to
12,000%).11 Unlike albumin, a very large molecule (66,500
Da) that does not permeate through intact conjunctival tis-
sue,24 we suspect that smaller molecules like prednisone (358
Da) and prednisolone (360 Da) readily cross the blood–tear
barrier under normal conditions, and are therefore not sig-
nificantly impacted by conjunctival inflammation.
However, we cannot exclude that larger amounts of cor-
ticosteroids actually reach the lacrimal fluid in eyes with
conjunctivitis; although the concurrent leakage of albumin
binding to free prednisolone would probably reduce its bio-
availability at the ocular surface.26 Further, physicochemical
properties other than molecular weight may explain dif-
ferences in lacrimal distribution between prednisone,
prednisolone, and other drugs reported in the veterinary
literature3,5,13—namely protein binding, lipophilicity, and
degree of ionization.27 In this study, the competitive nature
of plasma protein binding between prednisone and pred-
nisolone could justify the slightly higher lacrimal con-
centrations of prednisone in canine tears.28
The present study has a few limitations. First, the sample
size of our experiment was relatively small, and only fe-
males from a single dog breed were evaluated. Tear film PK
could theoretically differ in male versus female dogs,29 or
breeds other than Beagle, especially in brachycephalic dogs
in whom the lacrimal lipid layer is thin and corneal exposure
is large.30 Yet, previous studies did not find significant
differences between mesocephalic and brachycephalic dogs
with regard to tear film dynamics (tear volume, tear turnover
rate)31 or tear film drug concentrations.20
Second, it is possible that we did not find statistical dif-
ferences in tear film concentrations between healthy versus
conjunctivitis eyes because of the conjunctivitis model it-
self. Experimental induction of conjunctivitis, although ra-
pid and noninvasive,11 could have falsely lowered lacrimal
concentrations by causing reflex tearing and accelerated tear
turnover. We minimized this risk by inducing conjunctivitis
‡20 min before drug administration and sample collection,
but a small degree of ocular irritation could have lingered.
Regardless, increased tearing should not have affected drug
levels in a notable manner, as we did not find a significant
correlation between tear flow rate and prednisone/prednis-
olone levels in tears.
Finally, the present study used Schirmer strips to collect
tears in dogs, and although this method yielded sufficient
tear fluid for analysis, the method has several disadvantages
that could partly explain the large variability in tear con-
centrations noted among subjects. Not only do Schirmer
strips absorb tear fluid but they also retain a certain amount
of tear components (adsorption), the degree of which can
vary depending on the concentration.13
In this study, we minimized the impact of adsorption by
incorporating 2 important steps in our sample preparation:
(1) the internal standard was spiked onto the distal end of
Schirmer strips before tear extraction, and (2) standard
curves were processed in a similar manner to biological
samples. We also maximized the amount of drug extracted
from Schirmer strips by combining centrifugation with
solvent elution.13 Such combination may improve the assay
sensitivity (ie, able to detect lower concentrations), but the
process is very labor intensive and may not be necessary for
all drugs. Future studies should consider a pilot experiment
to assess the extraction efficacy of the combination method
versus centrifugation or solvent elution alone.
In conclusion, our data indicate that oral prednisone
might be safe and beneficial as adjunctive therapy for reflex
uveitis, ulcerative keratitis, or other ocular surface disease
in dogs. However, these preliminary pharmacokinetic find-
ings need to be complemented with prospective controlled
studies using systemic corticotherapy in diseased animals.
Similarly, future anatomical and physiological studies are
needed to better understand the role of conjunctivitis in
diffusion of systemically administered drugs into the tear
film.
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Appendix Table A1. Preparation of Schirmer Strips for Liquid Chromatography-Mass
Spectrometry Analysis
1 Transfer the Schirmer strip (wetted until 20-mm mark) to a 2-mL tubea using single-use tweezersb
2 Spike 5mL of 10 ng/mL prednisone internal standardc (10 ng/mL prepared in 1:1 acetonitrile:water) on the dry portion of
the strip (ie, 25–35 mm strip end)
3 Place the Schirmer strip into a 0.2-mL tubed that was prepunctured at its bottom with a 18-gauge needle
4 Secure the 0.2-mL tube into a 2-mL tube using adhesive tape
5 Centrifugee the combination for 2 min at 3,884 g to extract tear fluid out of the Schirmer strip into the 2-mL tube
6 Transfer the centrifuged strip to another 2-mL tube and cut it into multiple <5 mm pieces
7 Add 600mL of methyl tert-butyl ether (MTBE) into the tube containing the cut Schirmer strip
8 Grind for 1 min with a handheld pestlef
9 Store in +4C fridge for 2 h
10 Ultrasonic agitationg for 30 min
11 Centrifugeh for 1 min at 3,824 g
12 Transfer the fluid to a new 2-mL tube, leaving the cut/shredded Schirmer strip behind
13 Dry solvent with nitrogeni for 6–8 min at 5–8 psi
14 Add 75mL of 25% acetonitrile
15 Vortexj for 1 min
16 Centrifugeh for 1 min at 3,824 g
17 Transfer the fluid to the 2-mL tube containing the centrifuged tear sample (step #5)
18 Vortexj for 30 s
19 Centrifugeh for 30 s at 3,824 g
20 Transfer into LC-MS vialk containing a glass insert and a snap cap
21 Centrifugel at 1,074 g for 10 min
22 Transfer the sample from the glass insert to a 2-mL tube
23 Add 320mL of iced cold 100% acetonitrile
24 Centrifugeh for 10 min at 10,621 g
25 Transfer to a new 2-mL tube, leaving the precipitated proteins behind
26 Dry solvent with nitrogeni for 10–15 min
27 Add 100mL of 25% acetonitrile
28 Vortexj for 5 s
29 Transfer the sample to a new glass insert
30 Centrifugel at 998 g for 15 min
Steps 23–30 were added after the initial samples were deemed inappropriate for LC-MS analysis. The proteins contained in the
centrifuged tear sample were clogging the LC columns, so further precipitation in acetonitrile was required.
aTwo milliliter cryogenic vial; Fisherbrand, Fisher Scientific, Pittsburgh, PA.
bEvident disposable plastic tweezer; Evident, LLC, Union Hall, VA.
cPrednisone-d7; Toronto Research Chemicals, Inc., North York, Canada
dEppendorf safe-lock micro test tubes; Eppendorf North America, Inc., Westbury, NY.
eVWR mini centrifuge; VWR International, Mississauga, Ontario, Canada.
fArgos pestle mixer and pestle; Argos Technologies, Inc., Elgin, IL.
gBransonic ultrasonic cleaner; Branson Ultrasonics Corporation, Danbury, CT.
hEppendorf Centrifuge 5417C; Eppendorf North America, Inc., Hamburg, Germany.
iBiotage nitrogen evaporator; Biotage, LLC, Charlotte, NC.
jLP vortex mixer; Thermo Scientific, Inc., Waltham, MA.
kXpertek 2-mL 12 mm · 32 mm snap seal vial; P.J. Cobert Associates, Inc., St. Louis, MI.
lSorvall ST40 centrifuge, Thermo Scientific, Inc., Waltham, MA.
LC-MS, liquid chromatography-mass spectrometry.
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